CISION PRNewswire

24318 posts

YYForce Highlights US$21.9 Million in Reported Net Assets and Outlines Commercial Robotics and AI Platform Priorities

YYForce presents its reported book equity alongside its market capitalization to give…
Infineum Expands India Footprint with New Mumbai Office as Demand for High-Performance Lubricants Grows

Infineum Expands India Footprint with New Mumbai Office as Demand for High-Performance Lubricants Grows

MUMBAI, India, Nov. 2, 2026 /PRNewswire/ — Infineum, a global leader in…

TD Brings its Global Asset Management Businesses Under One Name

TD Global Investment Solutions will become TD Asset Management, simplifying how clients…

OncoC4 Appoints Dr. Dan Janiak as Chief Business Officer

ROCKVILLE, Md., Nov. 2, 2026 /PRNewswire/ — OncoC4, Inc., a late clinical-stage biopharmaceutical…

Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

Presentations to Explore Paxalisib’s Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov.…
BingX Wraps Up TOKEN2049 Singapore 2026 as Title Sponsor, Showcasing "Building the Future of Trading" Vision

BingX Wraps Up TOKEN2049 Singapore 2026 as Title Sponsor, Showcasing "Building the Future of Trading" Vision

PANAMA CITY, Nov. 2, 2026 /PRNewswire/ — BingX, the world’s leading multi-asset trading…

ECARX Signs MoU with Arm to advance next-generation high-performance AI computing across industry applications

MoU establishes framework to explore advanced solution development, including joint R&D and…

InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.

SHANGHAI, Nov. 2, 2026 /PRNewswire/ — InventisBio Co., Ltd. today announced that…